DexCom Announces FDA Approval of G5 Mobile App for Android Devices

DexCom Inc., a provider of continuous glucose monitoring (CGM) technology for people with diabetes, has received U.S. Food and Drug Administration (FDA) approval for the Dexcom G5 mobile app for Android devices.

Beginning this month (June), Android users will have access to the free app for the Dexcom G5 Mobile CGM System, allowing people with diabetes to view and monitor their glucose levels on their mobile devices to manage their diabetes in real time. The Dexcom G5 Mobile CGM System is the first and only CGM platform available for Android in the United States, complementing the 2015 iOS launch.
 
The Dexcom G5 Mobile is a compact CGM system that works to display real-time glucose activity on certain approved display devices. The launch of Dexcom G5 Mobile for Android allows people to manage their diabetes in a more personal and discrete way by providing glucose data on their Android mobile device, as well as the ability to share it safely and conveniently. This empowers them to make informed and timely decisions about their diabetes, resulting in better health outcomes.
 
“Providing Android users with access to the Dexcom G5 Mobile CGM System has been a priority for Dexcom,” said Kevin Sayer, president and CEO of Dexcom. “The new Android app has been thoughtfully designed with customer needs and feedback in mind. It focuses on delivering technology that empowers users by putting critical glucose information on their phones and is compatible with the most popular Android devices currently in the market.”
 
Once commercially available, the new app will make the Dexcom G5 Mobile available on millions of additional phones in the United States. The Dexcom G5 Mobile app for Android will initially be available on several Android devices from Samsung, Motorola and LG, as well as Android Wear watches.
 
DexCom Inc., headquartered in San Diego, Calif., develops and markets continuous glucose monitoring (CGM) products and tools.